BLS Pharmaceuticals Limited (ASX:BLS)
Australia · Delayed Price · Currency is AUD 1.125
-0.015 (-1.32%)
Sep 2, 2026, 11:33 AM AEST
BLS Pharmaceuticals Ratios and Metrics
Market cap in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 262 | 89 | 10 | 38 | 8 | 18 | |
Market Cap Growth | 141.43% | 767.35% | -73.09% | 395.11% | -57.14% | 180.00% |
Enterprise Value | 260 | 87 | 8 | 34 | 6 | 16 |
Last Close Price | 1.14 | 0.41 | 0.05 | 0.20 | 0.12 | 0.28 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | 28.72 | 18.11 | - | - | - | - |
PS Ratio | 5.47 | 3.03 | 1.06 | 7.18 | 16.57 | 8.13 |
PB Ratio | 13.00 | 7.33 | 3.10 | 2.53 | -21.05 | 9.27 |
P/TBV Ratio | 13.22 | 7.15 | 2.84 | 10.66 | - | 9.92 |
P/FCF Ratio | 925.31 | 21.09 | - | - | - | 337.34 |
P/OCF Ratio | 129.48 | 14.14 | - | - | - | 337.34 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
EV/Sales Ratio | 5.42 | 2.99 | 0.88 | 6.45 | 12.19 | 7.36 |
EV/EBITDA Ratio | 24.45 | 16.19 | - | - | - | - |
EV/EBIT Ratio | 26.24 | 17.16 | - | - | - | - |
EV/FCF Ratio | 917.41 | 20.79 | - | - | - | 305.44 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Debt / Equity Ratio | 0.27 | 0.13 | 0.22 | 0.04 | -1.09 | - |
Debt / EBITDA Ratio | 0.50 | 0.27 | - | - | - | - |
Debt / FCF Ratio | 18.94 | 0.36 | - | - | - | - |
Net Debt / Equity Ratio | -0.11 | -0.51 | -0.10 | -0.22 | -0.91 | -0.83 |
Net Debt / EBITDA Ratio | -0.22 | -1.13 | 0.29 | 1.92 | -0.78 | 4.50 |
Net Debt / FCF Ratio | -7.89 | -1.46 | 0.09 | 2.76 | -0.58 | -30.15 |
Asset Turnover | 1.94 | 2.23 | 0.79 | 0.58 | 0.30 | 0.73 |
Inventory Turnover | 3.67 | 6.30 | 3.78 | 6.98 | 1.48 | 2.20 |
Quick Ratio | 1.32 | 1.59 | 0.78 | 1.81 | 0.39 | 2.69 |
Current Ratio | 2.79 | 2.46 | 1.92 | 2.25 | 0.49 | 3.37 |
Return on Equity (ROE) | 66.14% | 63.64% | -141.75% | -26.18% | -62.97% | -21.82% |
Return on Assets (ROA) | 24.99% | 24.26% | -5.80% | -12.53% | -18.13% | -7.78% |
Return on Capital Employed (ROCE) | 40.70% | 38.70% | -29.90% | -12.10% | 122.60% | -19.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Earnings Yield | 3.42% | 5.52% | -130.21% | -5.10% | -6.43% | -2.77% |
FCF Yield | 0.11% | 4.74% | -36.53% | -3.13% | -7.38% | 0.30% |
Buyback Yield / Dilution | -11.95% | -11.36% | -43.61% | -83.52% | -14.42% | - |